Syntopia

SYNTOPIA is developing innovative tools enabling the pharmaceutical industry and CROs to use patients' primary cells on a large-scale in their in vitro cell-based assays. Our techbio platform combines high-throughput phenotypic screening on a microfluidic chip and in silico models to predict the evolution of key parameters of a biological system (100 times more) from a minimum of experiments (10 times less), paving the way for a faster and less costly understanding of biological systems. SYNTOPIA is a Parisian startup and a spin-off from the Laboratory of Biophysics and Evolution at ESPCI-PSL University. Our development is supported by prestigious national and European programs and its core technology is protected by two patents.